Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Goodin DS, et al. Among authors: frohman em. Neurology. 2002 Jan 22;58(2):169-78. doi: 10.1212/wnl.58.2.169. Neurology. 2002. PMID: 11805241 No abstract available.
Disease-modifying Therapies for Multiple Sclerosis.
Corboy JR, Goodin DS, Frohman EM. Corboy JR, et al. Among authors: frohman em. Curr Treat Options Neurol. 2003 Jan;5(1):35-54. doi: 10.1007/s11940-003-0021-0. Curr Treat Options Neurol. 2003. PMID: 12521562
The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Frohman EM, et al. Neurology. 2003 Sep 9;61(5):602-11. doi: 10.1212/01.wnl.0000082654.99838.ef. Neurology. 2003. PMID: 12963748
The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Goodin DS, et al. Among authors: frohman em. Neurology. 2003 Nov 25;61(10):1332-8. doi: 10.1212/01.wnl.0000095425.84407.39. Neurology. 2003. PMID: 14638950 Review.
A phase I trial of solubilized DR2:MBP84-102 (AG284) in multiple sclerosis.
Goodkin DE, Shulman M, Winkelhake J, Waubant E, Andersson P, Stewart T, Nelson S, Fischbein N, Coyle PK, Frohman E, Jacobs L, Holcenberg J, Lee M, Mocci S. Goodkin DE, et al. Neurology. 2000 Apr 11;54(7):1414-20. doi: 10.1212/wnl.54.7.1414. Neurology. 2000. PMID: 10751249 Clinical Trial.
242 results